Arpida's Superbug Treatment Found to Be Effective
Posted on: Monday, 16 July 2007, 12:10 CDT
Switzerland-based biotechnology company Arpida has reported that results from the second pivotal phase III trial of its intravenous iclaprim drug in patients with complicated skin and skin structure infections showed the treatment to be as effective as Pfizer's linezolid, which is marketed as Zyvox.
According to Arpida, the results of the second trial, called ASSIST-2, (Arpida's Skin and Skin Structure Infection STudies), validated the results of the first phase of testing, ASSIST-1. As well as confirming that Arpida's drug is as effective as Pfizer's, the trial also confirmed iclaprim's safety profile, as demonstrated in the first phase III trial, the company said.
Iclaprim targets a number of severe infections and is effective against methicillin-resistant Staphylococcus aureus (MRSA), a so-called superbug that is often contracted in hospitals. The infection is very difficult to treat and, according to Reuters, news of the antibiotic's benefits caused Arpida's shares to rise 27%.
Arpida said that as a result of the positive findings of the late stage trial, the company expects regulatory filing to be given before the end of 2007. Reuters also cited a spokesman for the company as saying that the drug is on target to be launched in 2008.
Dr Khalid Islam, president and CEO of Arpida, said: "We look to discuss the data with the regulatory authorities to define the path forward for the filing of a new drug application, which we expect to take place in the course of this year."
Source: Datamonitor
Related Articles
- Arpida Publishes Top-Line Data of Phase II "Intravenous-To-Oral" Switch Trial With Oral Iclaprim
- Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
- NuPathe Reports Positive Phase I Results for NP101, a Novel Transdermal Patch for Acute Migraine
- Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients With Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
- Arpida Initiates Enrolment in Phase II Trial of Oral Iclaprim
- Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
- Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data
- MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of Its MOR103 Program
- Arpida Reports Positive Results of Second Pivotal Phase III Trial With Intravenous Iclaprim in cSSSI
- Aeterna Phase I Results Support Cancer Compound
 |
 |
User Comments (0)
RSS Feeds